2020年8月20日

ImmPACT生物美國公司成立於FutuRx孵化器位於洛克錫安納,以色列,開發新穎的細胞療法治療癌症,今天宣布關閉1800萬美元股權融資。融資包括OrbiMed,強生公司創新——JJDC Inc . Inc .,武田公司RM全球合作夥伴(RMGP)生物製藥投資基金、諾華製藥風險基金,Bukwang製藥、Hayan健康網絡,公司和合資公司的投資合作夥伴。ImmPACT生物USA inc .)正在開發一套新穎的設計t細胞療法這一目標基因在實體腫瘤的損失。公司成立的見解教授吉迪恩總值(Migal研究所),與教授合作變色龍Eshhar設計第一嵌合抗原受體T細胞技術(汽車T)而CAR-T藥物提供了有意義的突破一些血液惡性腫瘤的治療,應用技術的進展甚微實體腫瘤。這種疾病是很少表現為腫瘤的抗原的表達,但基因組分析揭示了許多失去表達的機製。創始人教授吉迪恩總值ImmPACT的起源通過觀察解釋說,“基因工程細胞發展極大地在淋巴瘤和白血病,在很大程度上是因為淋巴細胞有選擇性的目標。我們需要新的目標策略解決固體腫瘤,很少有選擇性的目標發現,和抗原幾乎總是共享的不可或缺的組織。”Prof. Gross ultimately realized that, "Many solid tumors demonstrate genetic losses due to abnormal chromosomal maintenance - a fact that can be utilized to design new types of cellular immuno-oncology drugs." "We have built a world-class team and a promising pipeline to realize Prof. Gross' vision of targeting loss-of-gene features of solid tumors. We look forward to working with our investors to advance this pipeline and make the company a success," said Rick Kendall, Ph.D., CEO of ImmPACT Bio USA Inc. About ImmPACT Bio ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The company was founded based on the research of Prof. Gideon Gross of the Migal Research Institute and has been incubated in the FutuRx incubator since 2017. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.